

Rectal cancer: a review

Mohammad Sadegh Fazeli¹, Mohammad Reza Keramati²

Received: 10 November 2014

Accepted: 24 December 2014

Published: 31 January 2015

Abstract

Rectal cancer is the second most common cancer in large intestine. The prevalence and the number of young patients diagnosed with rectal cancer have made it as one of the major health problems in the world. With regard to the improved access to and use of modern screening tools, a number of new cases are diagnosed each year. Considering the location of the rectum and its adjacent organs, management and treatment of rectal tumor is different from tumors located in other parts of the gastrointestinal tract or even the colon. In this article, we will review the current updates on rectal cancer including epidemiology, risk factors, clinical presentations, screening, and staging. Diagnostic methods and latest treatment modalities and approaches will also be discussed in detail.

Keywords: Rectal cancer, Treatment, Review, Screening, Diagnosis, Staging, Treatment.

Cite this article as: Fazeli M.S, Keramati MR. Rectal cancer: a review. *Med J Islam Repub Iran* 2015 (31 January). Vol. 29:171.

Introduction

Rectal cancer is one of the frequent human malignant neoplasms and the second most common cancer in large intestine. Colorectal cancers (CRCs) are the second most common cancers in human and major public health problems worldwide (1).

Considering the different embryonic origin of the colon and the rectum, cancers arising from these two locations of the large bowel have several different distinctive features. The colon is arising from the midgut and the rectum from the hindgut. Gradient of hormone receptors are also different. These two serve different functions as well. The rectum is exposed to a more concentrated fecal matter in a direct way. Moreover, undigested matter traveling through the colon is coated with alkaline mucus. The different levels of pH in the colon and rectum may also influence susceptibility to environmental factors. (2) Therefore, different risk factors may be involved in these tumors.

With due regard to the location of the rec-

tum within the pelvic cavity and its relation with genitourinary organs, rectal tumors may present with special clinical manifestations different from other cancers within the gastrointestinal tract. During the past few years, diagnosis and management of rectal tumors as a separate entity from other parts of the colon has been considered greatly. With the help of rectosigmoidoscopy and new imaging modalities, these cancers can be diagnosed at earlier stages. Multimodality treatment approaches, including surgery, preoperative and postoperative chemo- or radiotherapies, have led to a better survival in these patients.

In this review article, we will review the current updates on rectal cancer. An overview on anatomy, epidemiology and risk factors will be discussed first and then we will go through clinical presentations, current staging and screening protocols and latest approaches on diagnosis and treatment modalities of rectal cancer.

1. Associate Professor of Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. mhfazeli@yahoo.com

2. (Corresponding author) Assistant Professor of Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. dr_morezak@yahoo.com

Anatomy of Rectum

The rectum is final portion of the large intestine between the sigmoid colon and the anal canal. It starts from the rectosigmoid junction at the level of the third sacral vertebra or the sacral promontory and terminates at the level of the anorectal ring. It is about 12-15 centimeters in length with an internal caliber similar to the sigmoid colon at the commencement. It dilates near its termination, forming the rectal ampulla.

Anatomic landmarks of rectum should be considered due to its importance in tumor staging, assessment of resectability and planning of surgery. The anal verge, most distal part of the anal canal, is an important surgical landmark. Lower border of the tumor located in rectum should be determined relative to this line. At the junction of the upper two-thirds and lower one-third, rectum separates into intra- and extraperitoneal portions by the anterior peritoneal reflection. Rectovesical pouch is a peritoneum-lined recess between the rectum and the posterior aspect of the bladder. The rectum is separated posteriorly from the pelvic nerves and the presacral venous by the presacral fascia. Denonvilliers' (rectoprostatic) fascia is located between the anterior aspect of the rectum and the prostate and seminal vesicles in men and the vagina in women.

Anatomic position of the rectal tumor in relation to anal sphincters is also an important issue in selecting patients for sphincter preservation surgery. Anal sphincter complex include internal and external sphincters separated by an intersphincteric plane. The internal sphincter is a thickened continuation of the inner smooth muscle layer of the rectum. The external sphincter is an extension of the puborectalis muscle and begins at the inferior insertion of the levator ani muscles.

Rectal wall comprises five layers including mucosa, submucosa, inner circular muscle, outer longitudinal muscle, and serosa. The proximal one third of the rectum is covered by peritoneum; but the mid and lower rectum lack serosa. Valves of Hous-

ston are three mucosal folds extending into the rectal lumen. The dentate or pectinate line is the transitional zone between columnar rectal mucosa and squamous anoderm. It is surrounded by columns of Morgagni which are longitudinal mucosal folds.

Anal transition zone is the 1 to 2 cm of mucosa just proximal to the dentate line with histologic characteristics of columnar, cuboidal, and squamous epithelium. (3-5)

Epidemiology

Rectal cancers are the second most common (28%) cancers in large intestine after proximal colon cancers (42%) (1). Therefore, rectal cancers have always been considered as a part of CRCs in related epidemiological studies. CRC, as one of the major public health problems, is the third most common cancer in men and the second in women in the world with a lifetime probability of 4.7-5% (6). It has also been reported as the third leading cause of cancer death in men and women in the United States (1).

Although geographical incidence of CRC varies worldwide, its pattern is similar among men and women. Currently, CRCs seem to be more common in developed regions of the world. The highest estimated rates is in Australia/New Zealand (44.8 and 32.2 per 100,000 in men and women respectively), and the lowest in Western Africa (4.5 and 3.8 per 100,000) (6). According to a recent data from the United States, approximately 136,830 new cases of CRC are diagnosed annually, including 40,000 rectal cancers (7). It is also estimated that 71,830 men and 65,000 women will be diagnosed with colorectal cancer and 26,270 men and 24,040 women will die of the disease in this country in 2014 (1).

With regard to the improved access to and use of screening and standard treatment, overall incidence rate has decreased by approximately 3% per year during the past decade. Although a large drop in the number of rectal cancers has been found in adults aged 65 and older (-1.5% for 50-64 years and 4.3% for ages above 65), this rate

has increased by 1.8% annually for rectal cancers among adults younger than 50 years. In contrast to proximal and distal colon cancers, the median age at diagnosis for rectal cancer is younger (63 years in men and 65 years in women). There is also a significant variation in tumor location by age, with a notable decrease in rectal tumors in older age. Male to female incidence rate ratio for rectal cancers also varies among different age groups as follows: 1.10 for 0-49 years, 1.19 for 50-64 years, 1.27 for 65-79 years, and 1.29 for those 80 years and older (1).

Rectal cancer's overall 5-year survival rate (66.5%) is slightly higher than for colon cancers (64.2%), but stage-specific survival is similar. Moreover, the survival rates do not vary significantly by sex. Mortality rate is 30-40% higher in men than in women, though this difference varies by age. Race and ethnicity can also affect the mortality rate; for instance recent reports from the United States show death rates in blacks are more than double those in Asians/Pacific Islanders (1). Although CRCs are more common in more developed regions, their mortality seems to be higher in the less developed regions of the world, reflecting a poorer survival in these countries. Highest estimated mortality rates in both sexes has been reported from Central and Eastern Europe (20.3 per 100,000 for men, 11.7 per 100,000 for women), and the lowest from Western Africa (3.5 and 3.0, respectively) (6).

Risk Factors

A large number of reviews and studies have considered risk factors in CRCs generally, however, a limited number of them have tried to separate environmental and genetic factors that can affect the likelihood of colon and rectal cancers (2,8).

Studies have confirmed that a family history of colorectal cancer appears to affect risk for colon cancer more strongly than risk for rectal cancer (2). Hereditary syndromes such as familial adenomatous polyposis (FAP), hereditary non-polyposis colo-

rectal cancer (HNPCC), and MUTYH-associated polyposis (MAP) are samples of familial colon cancer syndromes. Moreover, patients with a personal history of CRCs or adenomatous polyps of the colon are at risk for the future development of colon cancer. Prevalence of K-ras mutations and mutation patterns in the p53 gene in rectal cancers are also different from those seen in colon cancers (9).

Age and gender are important risk factors affecting both colon and rectal cancers (2). A statistically significant increased risk for colon cancer has been reported with increased height. For the Body Mass Index (BMI), there is a different effect on CRCs between men and women. A systematic review has reported that each 5 kg/m² increase in BMI is associated with a 24% and 9% increased incidence of CRCs in men and women, respectively (10). Moreover, there is a meaningful increased risk in the highest category of BMI among the women for rectal cancer (2).

Environmental factors such as diet and physical activity can also affect the risk. Contradictory results have been published on the role of calcium on rectal cancers. Wei et al (2) showed that patients with rectal cancers tended to have slightly higher folate and slightly lower calcium intake, whereas Wu et al. (11) found a significant association between calcium and cancers arising in the distal colon. It has also been shown that diets with higher milk and dairy product are associated with a significant reduction in the risk of colon cancer, not affecting the risk of rectal cancer (12). An inverse association has been shown between magnesium intake and the risk of both colon and rectum cancers in women (13). Physical activity has been found to be more strongly associated with colon cancer than rectal cancer. Beef, pork or lamb as a main dish, processed meat and alcohol are related to colon cancers (2). A slightly stronger association is reported between cigarette smoking and rectal cancer in comparison to colon cancer (2, 14). A history of radiation therapy for prostate cancer

is another risk factor of rectal cancer (15). According to a meta-analysis, risk of colon and rectal cancers among patients with diabetes mellitus was approximately 38% and 20% higher than non-diabetic patients, respectively (16).

Clinical Presentations

Although a large number of asymptomatic cases in early stages are diagnosed as a result of current screening programs worldwide, a significant number of cases are diagnosed after the onset of symptoms. Extension of a rectal tumor into adjacent organs or into the lumen of gastrointestinal tract leads to symptomatic presentation. Therefore, symptoms usually reflect at least a locally advanced cancer.

Rectal bleeding is the most common presentations of rectal cancer. In later stages of the disease, other symptoms such as tenesmus, incomplete stool evacuation, diminished caliber of stools cramping, pelvic and rectal pain or obstructive symptoms might present. Comparing the presenting symptoms of CRCs in general, we will notice that clinical manifestations differ depending on tumor location (i.e. ascending, transverse, or sigmoid colon, or rectum) (17). Hematochezia and change in bowel habit are more common in rectal cancers and left-sided CRCs; however, iron deficiency anemia from an unrecognized origin is more often caused by right-sided cancers. Abdominal pain can occur in both left- and right-sided tumors. It can be a symptom of partial obstruction, peritoneal dissemination of the tumor, intestinal perforation or even peritonitis. Patients suffering from metastatic rectal cancer may present with clinical symptoms referable to their metastatic site. Based on the venous drainage of the upper rectum via the portal system, most common site of hematogenous metastasis is liver, followed by the lungs and bone; however, distal rectum drains into the inferior rectal vein (and then into the inferior vena cava) and it may metastasize initially to the lungs (18-20).

In rare situations, rectal tumors can also

present emergently with intestinal obstruction, acute gastrointestinal bleeding or peritonitis following its perforation into the peritoneal cavity. Fistula formation into adjacent organs (such as bladder), fever of unknown origin, abscesses (due to a localized perforated cancer), bacteremia or sepsis (due to *Streptococcus bovis* or *Clostridium septicum*) has also been reported as other rare presentations (21-23).

Screening

The goal of colon and rectal cancer screening is to reach adequate target population coverage in order to reduce mortality through detection of early-stage adenocarcinomas and removal of adenomatous polyps. This leads to a reduction in incidence of advanced cancers (24). It is documented that around 30% of all CRCs are diagnosed by screening in asymptomatic individuals (25).

Screening in average-risk population

CRC screening in this group is performed using structural exams or stool tests which may be used alone or in combination to improve sensitivity. Structural exams can help in diagnosing both adenocarcinoma and adenomatous polyps, while stool tests are suited for detection of cancers. Structural exams, also called one step screening program, include colonoscopy, flexible sigmoidoscopy (FSIG), double-contrast barium enema (DCBE) and computed tomographic colonography (CTC). Stool tests are the initial method of a two-step program. Fecal occult blood tests (FOBT) can be done using guaiac-based (gFOBT), immunochemical-based (iFOBT or FIT) or fecal DNA methods. Currently, gFOBT is the most frequently used test in the CRC screening programs worldwide. In cases of positive FOBT, further evaluation with the structural exams has been recommended (24, 26). Although a group of rectal cancers can be detected on digital rectal examination, it is not recommended in current screening guidelines. (27)

A number of guidelines on CRC screen-

Table 1. Joint colorectal cancer screening guideline published by the American Cancer Society and the United States Multi-Society Task Force (ACS-MSTF)

Class:	Test	Interval
Tests that detect Adenomatous Polyps and Cancers	Flexible Sigmoidoscopy (FSIG)	Every 5 years, or
	Colonoscopy	Every 10 years, or
	Double-Contrast Barium Enema (DCBE)	Every 5 years, or
Tests that primarily detect Cancers	Computed Tomographic Colonography (CTC)	Every 5 years
	Guaiac-Based Fecal Occult Blood Test (gFOBT) with high sensitivity for cancer	Annual, or
	Fecal Immunohistochemical Test (FIT) With High Sensivity For Cancer	Annual, or
	Stool DNA Test With High Sensivity For Cancer	Uncertain Interval

ing are available. The joint guideline published in 2008 by the American Cancer Society, the United States Multi-Society Task Force on Colorectal Cancer (ACS-MSTF) and the American College of Radiology is one of the major protocols (24). Moreover, other guidelines have been issued by the National Comprehensive Cancer Network (NCCN) in 2013 (28), the Council of the European Union (CEU) in 2013 (29), the American College of Physicians (ACP) in 2012 (30), the American College of Gastroenterology (ACG) in 2009 (31), and the United States Preventive Services Task Force (USPSTF) in 2008 (32).

ACS-MSTF guideline (24) offers CRC screening beginning at age 50 for average-risk patients. Screening can be discontinued when the individual's estimated life expectancy is less than 10 years. It has a more stress on prevention rather than early detection and recommends that patients can choose specific tests within each class. The guideline has been summarized in Table 1. The gFOBT or FIT should be performed on three consecutive stool samples using a sensitive guaiac test. Positive tests need to be followed by colonoscopy. In patients who prefer FSIG, it should be done with insertion to 40cm or to splenic flexure.

Other guidelines have recommended different approaches for CRC screening. For instance, the CEU (29) guideline has recommended only the FOBT for screening individuals aged 50 to 74 years; whereas, colonoscopy is the preferred test in the NCCN (28) and the ACG (31) guidelines. Moreover, the ACG recommends screening beginning at age 45. The ACP suggests

screening average-risk patients starting at age 50 and stopping at age 75 years or in adults with a life expectancy less than 10 years. The USPSTF (32) recommends screening of adults age 50 to 75 years using annual sensitive FOBT, FSIG every 5 years in addition to sensitive FOBT every 3 years, or colonoscopy every 10 years.

Screening in high-risk population

Genetic predisposition is one of the most important risk factors for development of colon and rectum cancers. It is estimated that family history is a risk factor in 25% of patients with colorectal cancer. Patient with cancer susceptibility syndromes such as HNPCC and FAP are also at an increased risk (33). Multiple affected family members, history of CRC in first-degree relatives, and development of CRC at an early age (younger than 50 years) in the relatives are important risk factors (34, 35). Moreover, CRCs occur earlier in patients with a family history (36).

According to the latest guideline from the American College of Gastroenterology (ACG), screening with colonoscopy is recommended every 10 years beginning at age 50 for persons with a single first-degree relative diagnosed at age 60 or older with CRC or an advanced adenoma (larger than or equal to 1cm, high-grade dysplasia, or villous components). Whereas, in cases with a single first-degree relative diagnosed before 60 years with CRC or an advanced adenoma, or two or more first-degree relatives with these conditions at any age, screening with colonoscopy is recommended at age 40 or 10 years before the young-

est relative's diagnosis; and it needs to be repeated every five years (31).

The risk of CRC is increased in patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD) (37). Duration and extent of the inflammation are two important factors affecting the risk in UC. For instance, patients with pancolitis have the greatest risk after 8-10 years following the onset of symptoms (38, 39). The risk increases after 15-20 years in patients with left-side colitis (40). In contrast, the risk of cancer does not increase in patients with ulcerative proctitis and proctosigmoiditis (41). The American Gastroenterological Association (AGA) guideline recommends screening started after 8 years in patients with pancolitis and after 15 years in patients with left-side colitis, using colonoscopy every 1-2 years (37). Moreover, the American Society for Gastrointestinal Endoscopy (ASGE) has recommended four biopsies obtaining from every 10 cm of the colon from the cecum to the rectum during in each colonoscopy (42). In contrast, according to the American College of Gastroenterology (ACG) guideline, only patients who are surgical candidates are suggested for the annual surveillance colonoscopy (43). The British Society of Gastroenterology (BSG) recommends a surveillance colonoscopy 10 years after the onset of symptoms in all the patients irrespective to the extent and severity of the disease; but the interval depends on the duration and extent of disease and presence of additional risk factors (44). Patterns and factors affecting the risk of CRC in CD are similar to UC (45). Therefore, the AGA and the BSG guidelines have applied the same recommendations for CD.

An increased risk of CRC has also been detected in polyp syndromes such as HNPCC, or Lynch syndrome, FAP, MAP, juvenile polyposis (JPS) and Peutz-Jeghers syndrome (PJS). Biennial colonoscopy surveillance starting from age 25 to the age of 70-75 years has been offered for patients with HNPCC. In FAP mutation carriers, annual flexible sigmoidoscopy is recom-

mended from diagnosis; but in families where genetic linkage analysis is not possible, annual surveillance from age 13-15 until age 30 years, and every 3-5 years thereafter until age 60 should be done. In at-risk individuals and mutation carriers for the JPS, screening every 1-2 years is offered starting from age 15-18 years. For patients who are bi-allelic MUTYH carriers, screening with colonoscopy every 2-3 years is recommended from age 25. CRC screening has been recommended in patients with the PJS every 2 years from age 25 (44).

Diagnosis

Rectal cancers may be suspected from signs and symptoms or by rectal examination. Once suspected, a colonoscopy or an imaging study is required. It may also be discovered by the screening. Histologic tissue examination is then required to confirm the diagnosis followed by a proper staging.

Sigmoidoscopy and colonoscopy are two commonly used diagnostic and screening modalities for rectal cancers. Although flexible sigmoidoscopy is an accurate diagnostic method for rectal cancers, a colonoscopy is still required to evaluate other parts of the colon for synchronous colonic polyps or tumors that is found in 4% of patients. (46) Moreover, colonoscopy can remove polyps, biopsy lesions and visualize flat or non-polypoid adenomas throughout the large bowel. It is a precise tool with a miss rate of about 2.3% for rectal and sigmoid cancers. (47)

Double contrast barium enema (DCBE) is another diagnostic and screening tool used alone or together with flexible sigmoidoscopy. It has also been found to be superior to the Response Evaluation Criteria in Solid Tumors (RECIST) in evaluating the effect of chemoradiotherapy and predicting the likelihood of tumor recurrence (48), but its diagnostic yield is less than colonoscopy (49). Additionally, colonoscopy is recommended for all detected lesions by the DCBE to establish the histology and search for synchronous lesions.

Computed tomographic colonography (CTC) (also known as virtual colonoscopy) is another non-invasive and safe diagnostic tool. Not only CTC provides endoluminal visualization of the colon and rectum, but also it enables the examination of extracolonic organs (50). In a trial done by Atkin et al (51), the SIGGAR trial, CTC was recommended as a similarly sensitive, less invasive alternative to colonoscopy. CTC has also been suggested as a sensitive tool for detection of synchronous lesions in situations which a complete colonoscopy is not possible due to technical reasons (such as an obstructing cancer) or patient intolerance (52).

Other imaging modalities such as magnetic resonance imaging (MRI), endoscopic ultrasound (transrectal or transvaginal) are also used to determine the stage of the tumor. Transrectal ultrasound (TRUS) can distinguish localized cancers involving the mucosa and submucosa from those involved the muscularis propria or perirectal fat. (53) MRI is another accurate imaging test for staging evaluation of rectal cancer. Not only it has an established role in initial staging of the tumor, but also it can be utilized for evaluation of treatment response and local recurrence (5). The role of these two modalities in tumor staging will be discussed further in the staging section.

A number of serum markers have also been suggested for colon and rectum cancers, including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). Due to their low sensitivity for early-stage disease and possibility to increase in non-cancer medical conditions, they cannot be used as a screening or diagnostic test for CRCs (54, 55). CEA have also values in post-treatment follow-up, surgical treatment planning, and the evaluation of prognosis (54).

Staging

Once the diagnosis of rectal cancer is established, the local and distant extent of the tumor should be determined for further therapeutic approach. Imaging modalities

such as abdominopelvic CT or MRI and transrectal endoscopic ultrasound (TRUS) are frequently used for locoregional evaluation. Distant metastasis can be detected by chest CT, liver MRI or positron emission tomography (PET) scan.

In patient with diagnosed rectal cancer, CT scan is a helpful staging test for identifying local and distant metastasis and evaluation of tumor-related complications (such as obstruction, perforation or fistula formation) (56). The sensitivity of CT for detecting distant metastasis is higher than for detecting malignant lymph nodes or the local transmural tumor invasion (57). Although sensitivity of CT for assessment of perirectal lymph nodes is less than TRUS or MRI, its sensitivity for detection of malignant lymph nodes in rectal cancers is higher than colon cancers (58). Additionally, CT scan is not reliable in detecting small implants on peritoneal surfaces, with a sensitivity of 37% for peritoneal lesions 0.5-5cm in size (59, 60). Therefore, clinical benefit of routine abdominal and pelvic CT is controversial (61). Performing routine preoperative chest CT in rectal cancers has also been a matter of debate; but with due regard to the venous drainage of the lower rectum through the hemorrhoidal veins into the vena cava and higher probability of lung metastasis in rectal cancers, preoperative chest CT seems to be of more value in these tumors (62).

MRI is a useful modality in differentiating malignant tissues from the muscularis propria, and defining tumoral infiltration of the mesorectal fascia. MRI staging of rectal cancer can be performed using an endorectal surface coil, gradient coil systems or high resolution surface coils. Due to the ability of MRI to detect intranodal signals and irregularity of their borders, MRI has a higher sensitivity than EUS for the assessment of perirectal nodal involvement (63-66). According to a meta-analysis of 21 studies, published by Al-Sukhni et al, (66) MRI had 87% and 77% sensitivity for evaluation of the tumor size and nodal involvement, respectively. Its specificity was

75% for the size and 71% for the nodal status. Based on another meta-analysis, done by Niekel et al, (67) MRI has also been recommended as the preferred first-line imaging study for evaluating CRC liver metastases in patients who have not previously undergone therapy.

TRUS is an accurate modality for locoregional staging of rectal cancers using its ability to distinguish tumors involving the mucosa and submucosa from those involved the muscularis propria or perirectal fat (53). Comparing to CT and MRI, the TRUS has been superior for T staging of rectal cancer (68). In a meta-analysis published by Bipat et al, (69) TRUS was found to be more sensitive than CT and MRI in evaluation of both muscularis propria invasion and perirectal tissue invasion. In contrast, TRUS accuracy in evaluation of regional lymph nodes seems to be similar to CT and MRI (70). TRUS and MRI are also valuable modalities in evaluation of circumferential resection margin (CRM) before the surgical procedure. Involvement of the mesorectal fascia, which is the CRM during the surgical resection, is an important prognostic factor highly predictive of residual tumor and local recurrence. For

anterior rectal tumors, the CRM can be evaluated by TRUS or MRI, while MRI has been suggested for posterior tumors (71-75).

PET scans has not been recommended in routine preoperative staging of rectal cancers (76); while, as an adjunct to other tests it might be helpful in evaluation of patients with isolated colorectal cancer liver metastases to reduce the number of nontherapeutic laparotomies (77, 78) or localizing the site of recurrence in patients with a rising serum CEA level (79).

An accurate staging system can be helpful in choosing the best therapeutic option for patients suffering from cancers. It can also help physician to evaluate results of their management. The TNM (Tumor, Node and Metastasis) staging system for colorectal cancers provided by the American Joint Committee on Cancer (AJCC) (80) is currently used worldwide. The most recent 7th edition (2010) defines a revised staging system. Subdivision of T4, N1, N2, and M1 in addition to substaging of stage II is among the changes in the new edition. According to the recent staging system, the TNM classification for the staging of colorectal cancer is summarized in Tables 2 and 3.

Table 2. TNM (Tumor, Node and Metastasis) definition of colorectal cancers

Primary tumor (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ: intraepithelial or invasion of lamina propria
T1	Tumor invades submucosa
T2	Tumor invades muscularis propria
T3	Tumor invades through the muscularis propria into pericorectal tissues
T4a	Tumor penetrates to the surface of the visceral peritoneum
T4b	Tumor directly invades or is adherent to other organs or structures
Regional lymph nodes (N)	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in 1-3 regional lymph nodes
N1a	Metastasis in one regional lymph node
N1b	Metastasis in 2-3 regional lymph nodes
N1c	Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis
N2	Metastasis in four or more regional lymph nodes
N2a	Metastasis in 4-6 regional lymph nodes
N2b	Metastasis in seven or more regional lymph nodes
Distant metastasis (M)	
M0	No distant metastasis
M1	Distant metastasis
M1a	Metastasis confined to one organ or site (eg, liver, lung, ovary, nonregional node)
M1b	Metastases in more than one organ/site or the peritoneum

Table 3. Staging of colorectal cancers

Stage	T	N	M
0	Tis	N0	M0
I	T1	N0	M0
	T2	N0	M0
IIA	T3	N0	M0
IIB	T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-2	N1/N1c	M0
	T1	N2a	M0
IIIB	T3-T4a	N1/N1c	M0
	T2-T3	N2a	M0
	T1-T2	N2b	M0
IIIC	T4a	N2a	M0
	T3-T4a	N2b	M0
	T4b	N1-N2	M0
IVA	Any T	Any N	M1a
IVB	Any T	Any N	M1b

Treatment

Different types of treatment modalities have been proposed for patients with rectal cancer. Surgery is the mainstay of treatment for cases with resectable rectal cancers. According to the location of the tumor and the stage, surgical resection can be performed as the sole treatment modality or in combination with other neoadjuvant and/or adjuvant therapies (81).

Surgical Resection

Complete removal of the tumor and related lymphatic tissues is the primary goal of surgical resection. Other goals such as bowel continuity and anorectal sphincter preservation should also be considered when possible. The surgical options for resectable rectal cancers are local excision, sphincter-sparing procedures (such as low, very low, or ultra-low anterior resections), and abdominal perineal resection. Although more radical resections can be offered as potentially curative approaches for resectable tumors, other options such as local excision or sphincter-sparing procedures can be suggested to selected groups of patients. The choice of procedure is determined by the stage of the tumor, the location of the cancer from the dentate line and accommodating features of the pelvis (82).

The total mesorectal excision (TME) technique has been replaced the previous practice of blunt dissection of rectum from surrounding structures with better local

control and survival rates (83-85). Currently, it has been accepted as the standard surgical approach during sphincter-sparing procedures or abdominoperineal resections. TME is the removal of the perirectal areolar tissues including lateral and circumferential margins of the mesorectum using sharp and meticulous dissection in the avascular plane between the parietal and visceral pelvic fascia. A 5 cm mesorectal excision beyond the primary rectal tumor seems to be adequate (86-88). Reduced risk of postoperative genitourinary dysfunction due to preservation of the pelvic autonomic nerves is another advantage of this technique (89).

Obtaining histologically negative proximal, distal, and radial surgical margins of resection should also be considered in order to reduce the risk of a local recurrence (90). A 5 cm negative proximal margin seems to be adequate for most rectal cancers (87). In conjunction with a TME, a 2 cm negative distal margin is adequate for rectal cancers; however, a 1 cm distal negative margin has been accepted for cancers located at or below the mesorectal margin (82, 87, 91, 92). Preservation of the anorectal sphincter is recommended if it is possible to obtain the 1 cm negative distal margin (81).

Minimally invasive approach for surgical resection of rectal tumors has been found to be comparable to open surgery (93). Compared with the open techniques, the laparoscopic approach has resulted in similar completeness of resection and circumferential resection margins in addition to median tumor distance to the distal resection margin (94). Although no difference has been found between the female sexual function between these two techniques (open and laparoscopic), an increased risk of sexual dysfunction has been reported for men. Rates of bladder dysfunction are also similar following these two techniques (95). In another study, except for the mean operative time, patients undergoing a laparoscopic proctectomy had shorter length of hospital stay and lower rates of blood transfusion and postoperative complications (96).

Local Excision

Distal rectal tumors with nonaggressive features can be resected by local excision; however, it is not recommended for tumors located in proximal part of rectum. It can be performed through transanal, transsphincteric, or transsacral approaches. A local recurrence rate of 7% to 21% for T1 tumors has been reported for these procedures, therefore an annual follow-up with a sigmoidoscopy after five years has been recommended (82, 97-100).

Selected rectal T1N0M0 tumors located in middle to distal rectum with a diameter of less than 3 cm depicting favorable histological features (such as well differentiated, no vascular and/or neural invasion) are candidate for local excision. Presence of concurrent comorbidities that preclude a radical surgical operation and refusal of other surgical option are other indications for local excision. In the setting of a clinical trial, it may also be recommended for tumors deeper than the submucosa (>T1) with a complete response after neoadjuvant chemoradiation (82).

Transanal excision (TAE) is the most common local resection procedure for early rectal tumors. It is full-thickness excision of the rectal cancer with a negative deep margin and a minimum lateral margin of 1 cm. In cases with positive margins, an additional local or radical resection is needed (101, 102). Fewer postoperative complications (103) and high recurrence rate (104) are pros and cons of this technique, respectively. Transanal endoscopic microsurgery (TEM) is an alternative performed for tumors located 4-18 cm from the anal verge. The TAE approach is recommended for higher tumors (105-109). The transsphincteric approach (TSA), also called York-Mason procedure, used for cancers in the middle portion of the rectum beyond the reach of a TAE, but with a higher morbidity. Levator ani, puborectalis muscle and external anal sphincter are divided followed by a segmental resection and a primary closure. The transsacral approach, or the Kraske procedure, can be performed for

tumors located in the middle and posterior aspects of the rectum. In this approach, the rectum is circumferentially mobilized followed by partial or segmental resection of the rectum and a primary closure (110-112).

Low anterior resections (sphincter-sparing procedures):

A low anterior resection (LAR) is used for tumors located in the upper to middle parts of the rectum. The sigmoid colon and rectum is resected to a level where the distal margin is free of tumor followed by a primary anastomosis between the descending colon and the distal rectum.

For cancers located in the distal rectum without invasion to the anal sphincter, a very low anterior resection (VLAR) or ultra low anterior resection (ULAR) have been recommended (113). Provided the distal margin is clear of malignant cells, the anastomosis between the colon and anal sphincter can be performed as a straight side-to-end reservoir, a colonic J-pouch reservoir, or a transverse colectomy. The side-to-end coloanal anastomosis has been reported with a 51% success (complete fecal continence) in previous studies (114). The colonic J-pouch provides a larger reservoir with a side-to-side anastomosis at the distal 8 cm of the colon to create a pouch with an undistended volume capacity of 60-105 mL (115-119). Patients undergoing a colonic J-pouch have better short-term bowel function and lower morbidity, but long-term function and mortality are comparable in these two methods (120-122). The transverse colectomy is created by an 8-10 cm longitudinal colotomy between the colonic tenia, beginning 4-6 cm proximal to the distal end of the mobilized descending colon, and approximating the incision transversely. It is offered to patients who are not good candidates for the straight or J-pouch anastomosis (123).

In order to protect the anastomosis, a temporary diverting ileostomy has been recommended if the anastomosis is low, under tension, presence of an air leak on

proctoscopic testing, preoperative chemo-radiation, or history of immunosuppressive medication. (123, 124)

Abdominoperineal Resection

Abdominoperineal resection (APR) is an accepted surgical approach for low rectal tumors not indicated for sphincter-sparing procedures. It includes the resection of sigmoid colon, rectum, and anus followed by a permanent colostomy. It is indicated when achieving a negative distal margin is not possible with the sphincter-sparing procedures or as a salvage procedure for local recurrence or locally advanced rectal tumors. The introduction of circular stapling devices for low rectal anastomoses, the use of neoadjuvant therapy for downsizing rectal cancers and recent advances in sphincter saving procedures has resulted in an increase use of low anterior resections for low rectal tumors without sphincteric involvement (125).

Neoadjuvant Therapy

Neoadjuvant therapy has been strongly recommended for locally advanced cancers located in the middle or distal rectum. Presence of T4 rectal cancer is the most important indication for neoadjuvant treatment. It is also recommended in patients with node positive disease as well (82). Short-course radiotherapy (SCRT) and long-course chemoradiotherapy (LCCRT) are accepted approaches for delivering preoperative neoadjuvant therapy. The SCRT is done using a daily radiation dose of 5 Gy over 5 days. The LCCRT uses doses of 1.8-2 Gy over 5-6 weeks (to a total dose of 45-50.4 Gy) in addition to concurrent administration of 5-fluorouracil-based chemotherapy. Surgical resection is performed 8-12 weeks later (126, 127). Although neoadjuvant SCRT has been the preoperative treatment of choice in Northern Europe and Scandinavia, in North America and in some European countries LCCRT has become more accepted (82). Comparing SCRT and LCCRT, rates of sphincter preservation, local recurrence, disease free survival and

overall survival have been similar; however, complete pathological response was higher in patients receiving LCCRT (128, 129).

Several chemotherapeutic regimens have been used for the neoadjuvant therapy of rectal cancers. These regimens include infusional or bolus fluorouracil alone (130), and leucovorin plus fluorouracil (131). Other agents such as oral fluoropyrimidines (eg. Capecitabine) (132), Oxaliplatin (133), Irinotecan (134), Bevacizumab (135), Cetuximab (136), and Panitumumab (137) have also been studied.

The combination of neoadjuvant radiotherapy (LCCRT and SCRT) and optimal mesorectal excision has resulted in lower recurrence of rectal tumors, especially in tumors located 5-10 cm from the anal verge, with lymph node involvement and negative circumferential margins (138, 139). Long-term side effects including chronic bowel dysfunction and sexual dysfunction has also been reported in this setting (82). Patients who received preoperative SCRT had lower local recurrence and higher 5-year survival in comparison with the patients underwent surgery alone (140). Tumor regression and down-staging resulted from neoadjuvant LCCRT may also help complete resection of the tumor and may make a sphincter-saving procedure possible in low rectal tumors (130, 141-143). Therefore, SCRT is typically used in patients whose tumor margin threatens the mesorectal fascia and tumor down-staging would not improve resection or sphincter preservation (82).

Prognosis in patients undergoing neoadjuvant chemoradiotherapy is related to the final tumor stage and presence of lymph node involvement in the surgical specimen. Tumor Regression Grade (TRG), which is defined by degree of fibrosis and percentage of viable tumor, is another factor affecting the prognosis (144-146).

Adjuvant Therapy

Adjuvant therapy, in general, has been highly recommended for patients with stage

III or high-risk stage II rectal cancer. Postoperative chemoradiotherapy is the preferred adjuvant therapy for patients who have not received neoadjuvant therapy; while, postoperative chemotherapy is suggested for patients previously treated with neoadjuvant therapy (82). Adjuvant chemoradiotherapy has been shown to be effective in reducing local recurrence and mortality from the rectal cancer. Impaired perineal wound healing and small bowel toxicity are the disadvantages (147-149). Patients with a downstaged tumor due to a preoperative chemoradiation may also benefit from postoperative chemotherapy. In these cases, it is recommended to base adjuvant treatment decisions on the preoperative staging of the tumor (82).

Several regimens have been studied and used for the chemotherapy component of adjuvant treatment of rectal cancers. These regimen include bolus or infusional fluorouracil (150), the Roswell Park regimen (weekly bolus fluorouracil plus leucovorin) (151), the de Gramont regimen (short-term infusional fluorouracil and leucovorin) (152), capecitabine (an orally active fluoropyrimidines) (153) or oxaliplatin-based regimen such as FOLFOX (infusional fluorouracil and leucovorin plus oxaliplatin) (154) or CAPOX (Capecitabine plus oxaliplatin) (155) regimen.

Treatment of rectal cancer with liver metastases

Depending on the resectability of the primary tumor and the liver metastases, several treatment options are available for these patients. For patients with resectable colon cancer with resectable liver metastases, resection of the primary tumor followed by hepatic resection is the preferred strategy. In these cases a combined resection in one stage may also be performed. This approach is more complex for rectal cancers with potentially resectable liver metastases (156).

For rectal cancers, treatment may start with short-course radiotherapy or a long course chemoradiation followed by resec-

tion of the rectal cancer (156). Liver metastases will be resected at a later stage (157, 158). Treatment of liver metastases consists of radical resection and/or local ablative therapy (e.g. radiofrequency ablation) combined with adjuvant chemotherapy (159). A 5-year overall survival of around 30 % has been achieved after resection of all resectable primary and metastatic disease (160). However, some other studies showed a comparable survival rates after simultaneous colorectal and liver resection (161-164). Liver-first approach is another alternative, in which resection of the liver metastases is performed first followed by a radiation therapy to the rectum and resection of the rectal cancer at a later stage. Neoadjuvant chemotherapy has also been recommended for this approach (165-169).

Another treatment dilemma occurs in patients presenting with resectable rectal cancer but unresectable synchronous liver metastases. Palliation is the principal goal of treatment in symptomatic patients (170). The most common treatment strategy is to perform a palliative colorectal resection in order to treat or prevent complications of the primary tumor such as intestinal obstruction, perforation, or hemorrhage. Chemotherapy is administered after the resection to treat the metastatic disease (171-174). In asymptomatic patients, chemotherapy may be considered as the initial treatment (175). However, there is no clear evidence available on the best approach; initial resection of the primary tumor or initial systemic therapy (156).

Treatment of unresectable rectal cancer

A clear definition for unresectability of a rectal tumor has not been established yet. A fixed or adhesive tumor that cannot be resected from adjacent organs without leaving microscopic or gross residual disease at local site might be consider as an unresectable tumor. Thin cut MRI with pelvic phased-array coil is the modality of choice in evaluating the local tumor resectability. Depth of transmural invasion, nodal involvement, invasion into adjacent struc-

tures and circumferential margins can be assessed using MRI. In comparison, CT scan and endorectal ultrasound are less helpful in evaluation of local tumor resectability (176-180).

According to the guidelines, a multimodality plan including preoperative neoadjuvant chemoradiotherapy, multivisceral surgical resection (with or without intraoperative radiotherapy) and postoperative adjuvant chemotherapy are the current approach for unresectable rectal cancers (82, 87, 181, 182). Multivisceral resections, such as total pelvic exenteration (TPE) or its modifications, have led to good local control and survival (183-186). The TPE involves the removal of the rectum, anus, lower ureters, urinary bladder, and prostate in males; the uterus, ovaries and vagina are also removed in females (187, 188). Posterior pelvic exenteration has also been studied as a surgical modality in females with rectal tumor adherent or invaded to the uterus and vagina. It involves the removal of the rectum, sigmoid colon, internal reproductive organs, draining lymph nodes and pelvic peritoneum in women (189-191). A supralelevator pelvic exenteration is another option which involves the en bloc removal of the compromised organs similar to the TPE, preserving an adequate distal margin in the rectum. In this procedure, the perineal floor will be preserved; so, a primary colorectal anastomosis can be performed (192, 193). In a systematic review on 1049 patients underwent multivisceral resection for their rectal cancers, a local recurrence rate of 4.8- 61%, a complication rate of 37-100%, and a perioperative mortality rate of 0-25% was reported (194).

Treatment of locally recurrent rectal cancer

Proper management of locally recurrent rectal cancer has been a matter of debate. Depending on previous therapies and local extent of the recurrent tumor, treatment modalities such as surgery alone or with radiation therapy has been recommended. There are no strong data on the use of adjuvant chemotherapy for these patients.

Providing the possibility of complete resection of the tumor with negative margins, extensive surgical procedures such as pelvic exenteration (including partial sacrectomy) may result in long-term survival (195-201). Recurrent tumor involving nerve roots above the level of L1-2, proximal sacrum (S1, S2) extending to the sacral promontory, and involvement of paraaortic lymph nodes or the iliac vessels are not recommended for curative radical surgery. Extension through the greater sciatic notch, bilateral urethral obstruction and circumferential involvement of the pelvic wall are other contraindications for the curative radical surgery. Depending on possible curative resection, presence of liver or long metastases may not be a contraindication (202, 203). Pelvic radiotherapy is generally not recommended for previously irradiated patients; however, it has been reported in some studies (204-206). Intraoperative radiation therapy has also been reported with favorable results (207-211).

References

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA: a cancer journal for clinicians*. 2014;64(2):104-17. doi: 10. 3322/caac.21220.
2. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. *International journal of cancer Journal international du cancer*. 2004;108(3):433-42. PMID: 2903217. doi: 10. 1002/ijc.11540.
3. Beck DE RP, Saclarides TJ, Senagore AJ, Stamos MJ, Wexner SD. *The ASCRS Textbook of Colon and Rectal Surgery*. Second ed. New York: Springer; 2001. 946 p.
4. Brunickardi FC AD, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE. *Schwartz's Principles of Surgery*. Ninth ed: McGraw-Hill; 2010. 1888 p.
5. Furey E, Jhaveri KS. Magnetic Resonance Imaging in Rectal Cancer. *Magnetic resonance imaging clinics of North America*. 2014;22(2):165-90. doi: 10.1016/j.mric.2014.01.004.
6. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: International Agency for research on Cancer. World Health Organization; 2014 [cited 2014 5/13/2014]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.asp

- x.
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA*. 2014;64(1):9-29. doi: 10.3322/caac.21208.
 8. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology*. 2010;138(6):2029-43 e10. PMID: 2947820. doi: 10.1053/j.gastro.2010.01.057.
 9. Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. *Annals of Internal Medicine*. 2012;156(10):703-9. doi: 10.7326/0003-4819-156-10-201205150-00006.
 10. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*. 2008;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X.
 11. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. *Journal of the National Cancer Institute*. 2002;94(6):437-46.
 12. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. *Annals of Oncology*. 2012;23(1):37-45. doi: 10.1093/annonc/mdr269.
 13. Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. *JAMA*. 2005;293(1):86-9. doi: 10.1001/jama.293.1.86.
 14. Terry PD, Miller AB, Rohan TE. Prospective cohort study of cigarette smoking and colorectal cancer risk in women. *International Journal of Cancer*. 2002;99(3):480-3. doi: 10.1002/ijc.10364.
 15. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study. *Gastroenterology*. 2005;128(4):819-24.
 16. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *The American Journal of Gastroenterology*. 2011;106(11):1911-21; quiz 22. PMID: 3741453. doi: 10.1038/ajg.2011.301.
 17. Wilkes G, Hartshorn K. Clinical update: colon, rectal, and anal cancers. *Seminars in oncology nursing*. 2012;28(4):e1-22. doi: 10.1016/j.soncn.2012.09.012.
 18. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. *The American Journal of Gastroenterology*. 1999;94(10):3039-45. doi: 10.1111/j.1572-0241.1999.01454.x.
 19. Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. *East African Medical Journal*. 2008;85(6):259-62.
 20. Speights VO, Johnson MW, Stoltenberg PH, Rappaport ES, Helbert B, Riggs M. Colorectal cancer: current trends in initial clinical manifestations. *Southern Medical Journal*. 1991;84(5):575-8.
 21. Tsai HL, Hsieh JS, Yu FJ, Wu DC, Chen FM, Huang CJ, et al. Perforated colonic cancer presenting as intra-abdominal abscess. *International Journal of Colorectal Disease*. 2007;22(1):15-9. doi: 10.1007/s00384-006-0097-6.
 22. Alvarez JA, Baldonado RF, Bear IG, Alvarez P, Jorge JL. Anaerobic liver abscesses as initial presentation of silent colonic cancer. *HPB*. 2004;6(1):41-2. PMID: 2020643. doi: 10.1080/13651820310015798.
 23. Panwalker AP. Unusual infections associated with colorectal cancer. *Reviews of Infectious Diseases*. 1988;10(2):347-64.
 24. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology*. 2008;134(5):1570-95. doi: 10.1053/j.gastro.2008.02.002.
 25. Moiel D, Thompson J. Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? *The Permanente Journal*. 2011;15(4):30-8. PMID: 3267557.
 26. Zavoral M, Suchanek S, Majek O, Fric P, Minarikova P, Minarik M, et al. Colorectal cancer screening: 20 years of development and recent progress. *World journal of gastroenterology : WJG*. 2014;20(14):3825-34. PMID: 3983439. doi: 10.3748/wjg.v20.i14.3825.
 27. Collins JF, Lieberman DA, Durbin TE, Weiss DG, Veterans Affairs Cooperative Study G. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. *Annals of Internal Medicine*. 2005;142(2):81-5.
 28. Burt RW, Cannon JA, David DS, Early DS, Ford JM, Giardiello FM, et al. Colorectal cancer screening. *JNCCN*. 2013;11(12):1538-75.
 29. European Colorectal Cancer Screening Guidelines Working G, von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy*. 2013;45(1):51-9. doi: 10.1055/s-0032-1325997.
 30. Qaseem A, Denberg TD, Hopkins RH, Jr., Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. *Annals of Internal*

- Medicine. 2012;156(5):378-86. doi: 10.7326/0003-4819-156-5-201203060-00010.
31. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *The American Journal of Gastroenterology*. 2009;104(3):739-50. doi: 10.1038/ajg.2009.104.
32. Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine*. 2008;149(9):627-37.
33. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. *Gastroenterology*. 1997;112(2):594-642.
34. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. *The American Journal of Gastroenterology*. 2001;96(10):2992-3003. doi: 10.1111/j.1572-0241.2001.04677.x.
35. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. *European Journal of Cancer*. 2006;42(2):216-27. doi: 10.1016/j.ejca.2005.09.023.
36. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. *The New England Journal of Medicine*. 1994;331(25):1669-74. doi: 10.1056/NEJM 1994 12223312501.
37. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology*. 2010;138(2):746-74, 74 e1-4; quiz e12-3. doi: 10.1053/j.gastro.2009.12.035.
38. Collins RH, Jr., Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. *The New England Journal of Medicine*. 1987;316(26):1654-8. doi: 10.1056/NEJM198706253162609.
39. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. *Gut*. 1988;29(2):206-17. PMID: 1433302.
40. Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, Kreel I, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. *Gastroenterology*. 1979;77(2):290-4.
41. Levin B. Inflammatory bowel disease and colon cancer. *Cancer*. 1992;70(5 Suppl):1313-6.
42. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. *Gastrointestinal Endoscopy*. 2006;63(4):558-65. doi: 10.1016/j.gie.2006.02.005.
43. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *The American Journal of Gastroenterology*. 2010;105(3):501-23; quiz 24. doi: 10.1038/ajg.2009.727.
44. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut*. 2010;59(5):666-89. doi: 10.1136/gut.2009.179804.
45. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. *Gut*. 1994;35(7):950-4. PMID: 1374843.
46. Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. *Cancer Epidemiology*. 2011;35(5):442-7. doi: 10.1016/j.canep.2010.12.007.
47. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. *Gastroenterology*. 2007;132(1):96-102. doi: 10.1053/j.gastro.2006.10.027.
48. Murono K, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, et al. Barium Enema and CT Volumetry for Predicting Pathologic Response to Preoperative Chemoradiotherapy in Rectal Cancer Patients. *Diseases of the Colon and Rectum*. 2014;57(6):715-24. doi: 10.1097/DCR.000000000000070.
49. Irvine EJ, O'Connor J, Frost RA, Shorvon P, Somers S, Stevenson GW, et al. Prospective comparison of double contrast barium enema plus flexible sigmoidoscopy v colonoscopy in rectal bleeding: barium enema v colonoscopy in rectal bleeding. *Gut*. 1988;29(9):1188-93. PMID: 1434375.
50. Hong N, Park SH. CT colonography in the diagnosis and management of colorectal cancer: emphasis on pre- and post-surgical evaluation. *WJG*. 2014;20(8):2014-22. PMID: 3934471. doi: 10.3748/wjg.v20.i8.2014.
51. Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, et al. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. *Lancet*. 2013;381(9873):1194-202. doi: 10.1016/S0140-6736(12)62186-2.
52. Pullens HJ, van Leeuwen MS, Laheij RJ, Vlegaar FP, Siersema PD. CT-colonography after incomplete colonoscopy: what is the diagnostic yield? *Diseases of the Colon and Rectum*. 2013;56(5):593-9. doi:

10.1097/DCR.0b013e3182781668.

53. Beynon J, Foy DM, Roe AM, Temple LN, Mortensen NJ. Endoluminal ultrasound in the assessment of local invasion in rectal cancer. *The British Journal of Surgery*. 1986;73(6):474-7.

54. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *Journal of Clinical Oncology*. 2006;24(33):5313-27. doi: 10.1200/JCO.2006.08.2644.

55. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. *European Journal of Cancer*. 2003;39(6):718-27.

56. Horton KM, Abrams RA, Fishman EK. Spiral CT of colon cancer: imaging features and role in management. *Radiographics : a review publication of the Radiological Society of North America, Inc*. 2000;20(2):419-30. doi: 10.1148/radiographics.20.2.g00mc14419.

57. Hundt W, Braunschweig R, Reiser M. Evaluation of spiral CT in staging of colon and rectum carcinoma. *European Radiology*. 1999; 9(1):78-84.

58. Thoeni RF. Colorectal cancer. Radiologic staging. *Radiologic Clinics of North America*. 1997;35(2):457-85.

59. Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. *Cancer*. 1993;72(5):1631-6.

60. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. *Annals of Surgical Oncology*. 2009;16(2):327-33. doi: 10.1245/s10434-008-0234-2.

61. McAndrew MR, Saba AK. Efficacy of routine preoperative computed tomography scans in colon cancer. *The American Surgeon*. 1999;65(3):205-8.

62. Kirke R, Rajesh A, Verma R, Bankart MJ. Rectal cancer: incidence of pulmonary metastases on thoracic CT and correlation with T staging. *Journal of Computer Assisted Tomography*. 2007;31(4):569-71. doi: 10.1097/rct.0b013e318032e8c9.

63. Blomqvist L, Machado M, Rubio C, Gabriellsson N, Granqvist S, Goldman S, et al. Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography. *European Radiology*. 2000;10(4):653-60.

64. Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. *Radiology*. 2003;227(2):371-7. doi:

10.1148/radiol.2272011747.

65. Kim NK, Kim MJ, Yun SH, Sohn SK, Min JS. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. *Diseases of the Colon and Rectum*. 1999;42(6):770-5.

66. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. *Annals of Surgical Oncology*. 2012;19(7):2212-23. doi: 10.1245/s10434-011-2210-5.

67. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. *Radiology*. 2010;257(3):674-84. doi: 10.1148/radiol.10100729.

68. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. *International Journal of Colorectal Disease*. 2000;15(1):9-20.

69. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. *Radiology*. 2004;232(3):773-83. doi: 10.1148/radiol.2323031368.

70. Lahaye MJ, Engelen SM, Nelemans PJ, Beets GL, van de Velde CJ, van Engelshoven JM, et al. Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. *Seminars in ultrasound, CT, and MR*. 2005; 26(4):259-68.

71. Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. *Journal of Clinical Oncology*. 2014;32(1):34-43. doi: 10.1200/JCO.2012.45.3258.

72. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. *The British Journal of Surgery*. 2002;89(3):327-34. doi: 10.1046/j.0007-1323.2001.02024.x.

73. Arumugam PJ, Vivek V, Beynon J. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer (Br J Surg 2002; 89: 327-34). *The British Journal of Surgery*. 2002;89(8):1067. author reply doi: 10.1046/j.1365-2168.2002.02169_1.x.

74. Hall NR, Finan PJ, al-Jaberi T, Tsang CS, Brown SR, Dixon MF, et al. Circumferential margin involvement after mesorectal excision of rectal

cancer with curative intent. Predictor of survival but not local recurrence? *Diseases of the Colon and Rectum*. 1998;41(8):979-83.

75. Phang PT, Gollub MJ, Loh BD, Nash GM, Temple LK, Paty PB, et al. Accuracy of endorectal ultrasound for measurement of the closest predicted radial mesorectal margin for rectal cancer. *Diseases of the Colon and Rectum*. 2012;55(1):59-64. doi: 10.1097/DCR.0b013e318235b885.

76. Furukawa H, Ikuma H, Seki A, Yokoe K, Yuen S, Aramaki T, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. *Gut*. 2006;55(7):1007-11. PMID: 1856325. doi: 10.1136/gut.2005.076273.

77. Pawlik TM, Assumpcao L, Vossen JA, Buijs M, Gleisner AL, Schulick RD, et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. *Annals of Surgical Oncology*. 2009;16(2):371-8. doi: 10.1245/s10434-008-0230-6.

78. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. *Journal of Nuclear Medicine*. 2009;50(7):1036-41. doi: 10.2967/jnumed.109.063040.

79. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). *European Journal of Cancer*. 2001;37(7):862-9.

80. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, et al. *AJCC (American Joint Committee on Cancer) Cancer Staging Manual*. 7th ed. New York: Springer; 2010.

81. McCourt M, Armitage J, Monson JR. Rectal cancer. *The Surgeon*. 2009;7(3):162-9.

82. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). *Diseases of the colon and rectum*. 2013;56(5):535-50. doi: 10.1097/DCR.0b013e31828cb66c.

83. Heald RJ, Ryall R. Recurrent cancer after restorative resection of the rectum. *British Medical Journal*. 1982;284(6318):826-7. PMID: 1496349.

84. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet*. 2009;373(9666):821-8. PMID: 2668948. doi: 10.1016/S0140-6736(09)60485-2.

85. Maurer CA, Renzulli P, Kull C, Kaser SA, Mazzucchelli L, Ulrich A, et al. The impact of the introduction of total mesorectal excision on local

recurrence rate and survival in rectal cancer: long-term results. *Annals of Surgical Oncology*. 2011;18(7):1899-906. doi: 10.1245/s10434-011-1571-0.

86. Bokey EL, Ojerskog B, Chapuis PH, Dent OF, Newland RC, Sinclair G. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. *The British Journal of Surgery*. 1999;86(9):1164-70. doi: 10.1046/j.1365-2168.1999.01216.x.

87. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. *Journal of the National Cancer Institute*. 2001;93(8):583-96.

88. Nagtegaal ID, van de Velde CJ, Marijnen CA, van Krieken JH, Quirke P, Dutch Colorectal Cancer G, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. *Journal of Clinical Oncology*. 2005;23(36):9257-64. doi: 10.1200/JCO.2005.02.9231.

89. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. *Lancet*. 1993;341(8843):457-60.

90. Kim YW, Kim NK, Min BS, Huh H, Kim JS, Kim JY, et al. Factors associated with anastomotic recurrence after total mesorectal excision in rectal cancer patients. *Journal of Surgical Oncology*. 2009;99(1):58-64. doi: 10.1002/jso.21166.

91. Wolmark N, Cruz I, Redmond CK, Fisher B, Fisher ER. Tumor size and regional lymph node metastasis in colorectal cancer. A preliminary analysis from the NSABP clinical trials. *Cancer*. 1983;51(7):1315-22.

92. Wolmark N, Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. *National Surgical Adjuvant Breast and Bowel Project. Annals of Surgery*. 1986;204(4):480-9. PMID: 1251324.

93. Lujan J, Valero G, Hernandez Q, Sanchez A, Frutos MD, Parrilla P. Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer. *The British Journal of Surgery*. 2009;96(9):982-9. doi: 10.1002/bjs.6662.

94. van der Pas MH, Haglund E, Cuesta MA, Furst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *The Lancet Oncology*. 2013;14(3):210-8. doi: 10.1016/S1470-2045(13)70016-0.

95. Quah HM, Jayne DG, Eu KW, Seow-Choen F. Bladder and sexual dysfunction following laparoscopically assisted and conventional open mesorectal resection for cancer. *The British Journal of Surgery*. 2002;89(12):1551-6. doi: 10.1046/j.1365-2168.2002.02275.x.

96. Greenblatt DY, Rajamanickam V, Pugely AJ, Heise CP, Foley EF, Kennedy GD. Short-term outcomes after laparoscopic-assisted proctectomy

- for rectal cancer: results from the ACS NSQIP. *Journal of the American College of Surgeons*. 2011;212(5):844-54. PMID: 3488426. doi: 10.1016/j.jamcollsurg.2011.01.005.
97. Greenberg JA, Shibata D, Herndon JE, 2nd, Steele GD, Jr., Mayer R, Bleday R. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. *Diseases of the Colon and Rectum*. 2008;51(8):1185-91; discussion 91-4. doi: 10.1007/s10350-008-9231-6.
98. Wentworth S, Russell GB, Tuner, II, Levine EA, Mishra G, Waters GS, et al. Long-term results of local excision with and without chemoradiation for adenocarcinoma of the rectum. *Clinical Colorectal Cancer*. 2005;4(5):332-5.
99. Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, et al. Long-term results of local excision for rectal cancer. *Annals of Surgery*. 2002;236(4):522-29; discussion 9-30. PMID: 1422607. doi: 10.1097/01.SLA.0000029001.10244.61.
100. Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. *WJG*. 2006;12(20):3186-95.
101. Endreth BH, Myrvold HE, Romundstad P, Hestvik UE, Bjerkeset T, Wibe A, et al. Transanal excision vs. major surgery for T1 rectal cancer. *Diseases of the Colon and Rectum*. 2005;48(7):1380-8. doi: 10.1007/s10350-005-0044-6.
102. Garcia-Aguilar J, Mellgren A, Sirivongs P, Buie D, Madoff RD, Rothenberger DA. Local excision of rectal cancer without adjuvant therapy: a word of caution. *Annals of Surgery*. 2000;231(3):345-51. PMID: 1421005.
103. Ptok H, Marusch F, Meyer F, Schubert D, Koeckerling F, Gastinger I, et al. Oncological outcome of local vs radical resection of low-risk pT1 rectal cancer. *Archives of Surgery*. 2007;142(7):649-55; discussion 56. doi: 10.1001/archsurg.142.7.649.
104. Gonzalez QH, Heslin MJ, Shore G, Vickers SM, Urist MM, Bland KI. Results of long-term follow-up for transanal excision for rectal cancer. *The American Surgeon*. 2003;69(8):675-8; discussion 8.
105. Neary P, Makin GB, White TJ, White E, Hartley J, MacDonald A, et al. Transanal endoscopic microsurgery: a viable operative alternative in selected patients with rectal lesions. *Annals of Surgical Oncology*. 2003;10(9):1106-11.
106. Langer C, Liersch T, Suss M, Siemer A, Markus P, Ghadimi BM, et al. Surgical cure for early rectal carcinoma and large adenoma: transanal endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and radical resection. *International Journal of Colorectal Disease*. 2003;18(3):222-9. doi: 10.1007/s00384-002-0441-4.
107. Demartines N, von Flue MO, Harder FH. Transanal endoscopic microsurgical excision of rectal tumors: indications and results. *World Journal of Surgery*. 2001;25(7):870-5.
108. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO. Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. *Annals of Surgery*. 2009;249(5):776-82. doi: 10.1097/SLA.0b013e3181a3e54b.
109. Palma P, Freudenberg S, Samel S, Post S. Transanal endoscopic microsurgery: indications and results after 100 cases. *Colorectal Disease*. 2004;6(5):350-5. doi: 10.1111/j.1463-1318.2004.00671.x.
110. Westbrook KC, Lang NP, Broadwater JR, Thompson BW. Posterior surgical approaches to the rectum. *Annals of Surgery*. 1982;195(6):677-85. PMID: 1352653.
111. Gimbel MI, Paty PB. A current perspective on local excision of rectal cancer. *Clinical Colorectal Cancer*. 2004;4(1):26-35; discussion 6-7.
112. Onaitis M, Ludwig K, Perez-Tamayo A, Gottfried M, Russell L, Shaddock P, et al. The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. *Journal of Surgical Oncology*. 2006;94(3):194-202. doi: 10.1002/jso.20591.
113. Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. *Cancer*. 1998;83(11):2408-18.
114. Paty PB, Enker WE, Cohen AM, Minsky BD, Friedlander-Klar H. Long-term functional results of coloanal anastomosis for rectal cancer. *American Journal of Surgery*. 1994;167(1):90-4; discussion 4-5.
115. de la Fuente SG, Mantyh CR. Reconstruction techniques after proctectomy: what's the best? *Clinics in Colon and Rectal Surgery*. 2007;20(3):221-30. PMID: 2789510. doi: 10.1055/s-2007-984866.
116. Lazorthes F, Gamagami R, Chiotasso P, Istvan G, Muhammad S. Prospective, randomized study comparing clinical results between small and large colonic J-pouch following coloanal anastomosis. *Diseases of the Colon and Rectum*. 1997;40(12):1409-13.
117. Banerjee AK, Parc R. Prediction of optimum dimensions of colonic pouch reservoir. *Diseases of the Colon and Rectum*. 1996;39(11):1293-5.
118. Parc R, Tiret E, Frileux P, Moszkowski E, Loygue J. Resection and colo-anal anastomosis with colonic reservoir for rectal carcinoma. *The British journal of surgery*. 1986;73(2):139-41.
119. Lazorthes F, Fages P, Chiotasso P, Lemozy J, Bloom E. Resection of the rectum with construction of a colonic reservoir and colo-anal anastomosis for carcinoma of the rectum. *The British Journal of Surgery*. 1986;73(2):136-8.
120. Joo JS, Latulippe JF, Alabaz O, Weiss EG,

- Nogueras JJ, Wexner SD. Long-term functional evaluation of straight coloanal anastomosis and colonic J-pouch: is the functional superiority of colonic J-pouch sustained? *Diseases of the Colon and Rectum*. 1998;41(6):740-6.
121. Machado M, Nygren J, Goldman S, Ljungqvist O. Similar outcome after colonic pouch and side-to-end anastomosis in low anterior resection for rectal cancer: a prospective randomized trial. *Annals of Surgery*. 2003;238(2):214-20. PMID: 1422690. doi: 10.1097/01.sla.0000080824.10891.e1.
122. Ho YH, Seow-Choen F, Tan M. Colonic J-pouch function at six months versus straight coloanal anastomosis at two years: randomized controlled trial. *World Journal of Surgery*. 2001;25(7):876-81.
123. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. *The Cochrane database of systematic reviews*. 2008(2):CD006040. doi: 10.1002/14651858.CD006040.pub2.
124. Huser N, Michalski CW, Erkan M, Schuster T, Rosenberg R, Kleeff J, et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. *Annals of Surgery*. 2008;248(1):52-60. doi: 10.1097/SLA.0b013e318176bf65.
125. Murrell ZA, Dixon MR, Vargas H, Arnell TD, Kumar R, Stamos MJ. Contemporary indications for and early outcomes of abdominoperineal resection. *The American Surgeon*. 2005;71(10):837-40.
126. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet*. 2009;373(9666):811-20. PMID: 2668947. doi: 10.1016/S0140-6736(09)60484-0.
127. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevich-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *The New England Journal of Medicine*. 2006;355(11):1114-23. doi: 10.1056/NEJMoa060829.
128. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. *Radiotherapy and Oncology*. 2004;72(1):15-24. doi: 10.1016/j.radonc.2003.12.006.
129. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *The British Journal of Surgery*. 2006;93(10):1215-23. doi: 10.1002/bjs.5506.
130. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *The New England Journal of Medicine*. 2004;351(17):1731-40. doi: 10.1056/NEJMoa040694.
131. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *Journal of Clinical Oncology*. 2006;24(28):4620-5. doi: 10.1200/JCO.2006.06.7629.
132. Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. *British Journal of Cancer*. 2007;97(10):1333-7. PMID: 2360245. doi: 10.1038/sj.bjc.6604042.
133. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *Journal of Clinical Oncology*. 2011;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911.
134. Navarro M, Dotor E, Rivera F, Sanchez-Rovira P, Vega-Villegas ME, Cervantes A, et al. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2006;66(1):201-5. doi: 10.1016/j.ijrobp.2006.04.007.
135. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2010;76(3):824-30. doi: 10.1016/j.ijrobp.2009.02.037.
136. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *Journal of Clinical Oncology*. 2012;30(14):1620-7. doi: 10.1200/JCO.2011.39.6036.
137. Helbling D, Bodoky G, Gaultschi O, Sun H, Bosman F, Gloor B, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced

- rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. *Annals of Oncology*. 2013;24(3):718-25. doi: 10.1093/annonc/mds519.
138. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *The New England Journal of Medicine*. 2001;345(9):638-46. doi: 10.1056/NEJMoa010580.
139. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *The Lancet Oncology*. 2011;12(6):575-82. doi: 10.1016/S1470-2045(11)70097-3.
140. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. *The New England Journal of Medicine*. 1997;336(14):980-7. doi: 10.1056/NEJM199704033361402.
141. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. *The Cochrane database of systematic reviews*. 2009(1):CD006041. doi: 10.1002/14651858.CD006041.pub2.
142. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer*. 2008;113(1):57-64. doi: 10.1002/cncr.23516.
143. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Annals of Surgery*. 2009;249(2):236-42. doi: 10.1097/SLA.0b013e318195e17c.
144. Rodel C, Martus P, Papadopoulos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *Journal of Clinical Oncology*. 2005;23(34):8688-96. doi: 10.1200/JCO.2005.02.1329.
145. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. *Diseases of the Colon and Rectum*. 2002;45(8):1051-6.
146. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2005;62(3):752-60. doi: 10.1016/j.ijrobp.2004.11.017.
147. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. *Journal of the National Cancer Institute*. 1988;80(1):21-9.
148. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. *The New England Journal of Medicine*. 1991;324(11):709-15. doi: 10.1056/NEJM199103143241101.
149. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet*. 2007;370(9604):2020-9. doi: 10.1016/S0140-6736(07)61866-2.
150. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *Journal of Clinical Oncology*. 2006;24(22):3542-7. doi: 10.1200/JCO.2005.04.9544.
151. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. *Journal of Clinical Oncology*. 2005;23(34):8671-8. doi: 10.1200/JCO.2004.00.5686.
152. Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. *Journal of Clinical Oncology*. 2007;25(24):3732-8. doi: 10.1200/JCO.2007.12.2234.
153. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *The Lancet Oncology*. 2012;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X.
154. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. *British Journal of Cancer*. 2002;87(4):393-9. PMID: 2376131. doi: 10.1038/sj.bjc.6600467.
155. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. *Journal of Clinical Oncology*. 2008;26(21):3523-9. doi: 10.1200/JCO.2007.

15.4138.

156. Ruers TJ, Hagendoorn J. Treatment dilemmas in patients with synchronous colorectal liver metastases. *Recent Results in Cancer Research*. 2012;196:37-49. doi: 10.1007/978-3-642-31629-6_3.

157. Adam R. Colorectal cancer with synchronous liver metastases. *The British Journal of Surgery*. 2007;94(2):129-31. doi: 10.1002/bjs.5764.

158. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. *Annals of Surgical Oncology*. 2007;14(12):3481-91. doi: 10.1245/s10434-007-9522-5.

159. Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, et al. The role of local therapy in the management of lung and liver oligometastases. *Nature Reviews Clinical Oncology*. 2011;8(7):405-16. doi: 10.1038/nrclinonc.2011.75.

160. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *British Journal of Cancer*. 2006;94(7):982-99. PMID: 2361241. doi: 10.1038/sj.bjc.6603033.

161. Vassiliou I, Arkadopoulos N, Theodosopoulos T, Fragulidis G, Marinis A, Kondi-Paphiti A, et al. Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. *WJG*. 2007;13(9):1431-4.

162. Weber JC, Bachellier P, Oussultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. *The British Journal of Surgery*. 2003;90(8):956-62. doi: 10.1002/bjs.4132.

163. Thelen A, Jonas S, Benckert C, Spinelli A, Lopez-Hanninen E, Rudolph B, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. *International Journal of Colorectal Disease*. 2007;22(10):1269-76. doi: 10.1007/s00384-007-0286-y.

164. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O. Combined colon and hepatic resection for synchronous colorectal liver metastases. *Journal of Surgical Oncology*. 2001;78(1):17-21.

165. Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. *JAMA Surgery*. 2013;148(4):385-91. doi: 10.1001/jamasurg.2013.1216.

166. De Rosa A, Gomez D, Brooks A, Cameron IC. "Liver-first" approach for synchronous colorectal liver metastases: is this a justifiable approach? *Journal of Hepato-biliary-pancreatic Sciences*. 2013;20(3):263-70. doi: 10.1007/s00534-012-0583-x.

167. Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, et al. A systematic

review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. *HPB*. 2014;16(2):101-8. PMID: 3921004. doi: 10.1111/hpb.12083.

168. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, et al. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. *Digestive Surgery*. 2008;25(6):430-5. doi: 10.1159/000184734.

169. de Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. *HPB*. 2011;13(10):745-52. PMID: 3210977. doi: 10.1111/j.1477-2574.2011.00372.x.

170. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. *The Surgical Clinics of North America*. 1997;77(1):27-48.

171. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *Journal of Clinical Oncology*. 2009;27(22):3677-83. PMID: 2720081. doi: 10.1200/JCO.2008.20.5278.

172. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *Journal of the National Cancer Institute*. 2004;96(19):1420-5. doi: 10.1093/jnci/djh275.

173. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. *Journal of Clinical Oncology*. 2008;26(35):5721-7. PMID: 2645101. doi: 10.1200/JCO.2008.17.7147.

174. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. *Journal of Clinical Oncology*. 2005;23(36):9441-2. doi: 10.1200/JCO.2005.04.4792.

175. Sarela A, O'Riordain DS. Rectal adenocarcinoma with liver metastases: management of the primary tumour. *The British Journal of Surgery*. 2001;88(2):163-4. doi: 10.1046/j.1365-2168.2001.01698.x.

176. Dresen RC, Kusters M, Daniels-Gooszen AW, Cappendijk VC, Nieuwenhuijzen GA, Kessels AG, et al. Absence of tumor invasion into pelvic structures in locally recurrent rectal cancer: prediction with preoperative MR imaging. *Radiology*. 2010;256(1):143-50. doi: 10.1148/radiol.10090725.

177. Beets-Tan RG, Beets GL, Borstlap AC, Oei TK, Teune TM, von Meyenfeldt MF, et al. Preoperative assessment of local tumor extent in

advanced rectal cancer: CT or high-resolution MRI? *Abdominal Imaging*. 2000;25(5):533-41.

178. Farouk R, Nelson H, Radice E, Mercill S, Gunderson L. Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers. *American Journal of Surgery*. 1998;175(4):283-7.

179. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *Journal of Clinical Oncology*. 2011;29(28):3753-60. doi: 10.1200/JCO.2011.34.9068.

180. Genovesi D, Filippone A, Ausili Cefaro G, Trignani M, Vinciguerra A, Augurio A, et al. Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results of a monoinstitutional prospective study. *European Journal of Surgical Oncology*. 2013;39(10):1071-8. doi: 10.1016/j.ejso.2013.07.090.

181. Hoffmann M, Phillips C, Oevermann E, Killaitis C, Roblick UJ, Hildebrand P, et al. Multivisceral and standard resections in colorectal cancer. *Langenbeck's archives of surgery*. 2012;397(1):75-84. doi: 10.1007/s00423-011-0854-z.

182. Lopez MJ. Multivisceral resections for colorectal cancer. *Journal of Surgical Oncology*. 2001;76(1):1-5.

183. Nakafusa Y, Tanaka T, Tanaka M, Kitajima Y, Sato S, Miyazaki K. Comparison of multivisceral resection and standard operation for locally advanced colorectal cancer: analysis of prognostic factors for short-term and long-term outcome. *Diseases of the Colon and Rectum*. 2004;47(12):2055-63. doi: 10.1007/s10350-004-0716-7.

184. Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. *Annals of Surgery*. 2002;235(2):217-25. PMID: 1422417.

185. Luna-Perez P, Rodriguez-Ramirez SE, De la Barrera MG, Zeferino M, Labastida S. Multivisceral resection for colon cancer. *Journal of Surgical Oncology*. 2002;80(2):100-4. doi: 10.1002/jso.10105.

186. Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CH. Population-based assessment of the surgical management of locally advanced colorectal cancer. *Journal of the National Cancer Institute*. 2006;98(20):1474-81. doi: 10.1093/jnci/djj396.

187. Rodriguwz-Bigas MA, Petrelli NJ. Pelvic exenteration and its modifications. *American Journal of Surgery*. 1996;171(2):293-8.

188. Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. *Annals of Surgical Oncology*. 2006;13(5):612-23. doi: 10.1245/ASO.2006.03.082.

189. Bannura GC, Barrera AE, Cumsille MA, Contreras JP, Melo CL, Soto DC, et al. Posterior pelvic exenteration for primary rectal cancer. *Colorectal Disease*. 2006;8(4):309-13. doi: 10.1111/j.1463-1318.2005.00938.x.

190. Lohsiriwat V, Lohsiriwat D. Comparison of immediate surgical outcomes between posterior pelvic exenteration and standard resection for primary rectal cancer: a matched case-control study. *WJG*. 2008;14(15):2414-7. PMID: 2705100.

191. Puntambekar SP, Kumthekar P, Agarwal-Joshi G, Joshi S, Nadkarni A. Total laparoscopic posterior pelvic exenteration: a case report of low anterior resection with en bloc partial vaginectomy with sphincter preservation and handsewn coloanal anastomosis for locoregionally advanced carcinoma of rectum invading female genital tract. *Surgical Laparoscopy, Endoscopy & Percutaneous Techniques*. 2013;23(1):e22-3. doi: 10.1097/SLE.0b013e318265a2db.

192. Dias AR, Nahas SC. Modified supralelevator pelvic exenteration for the treatment of locally advanced rectal cancer with vaginal and uterine invasion. *Surgery Today*. 2013;43(6):702-4. doi: 10.1007/s00595-012-0298-2.

193. Moutardier V, Houvenaeghel G, Lelong B, Mokart D, Delpero JR. Colorectal function preservation in posterior and total supralelevator exenteration for gynecologic malignancies: an 89-patient series. *Gynecologic Oncology*. 2003;89(1):155-9.

194. Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. *Diseases of the Colon and Rectum*. 2013;56(4):519-31. doi: 10.1097/DCR.0b013e31827a7868.

195. Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ, et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. *Journal of Clinical Oncology*. 2003;21(19):3623-8. doi: 10.1200/JCO.2003.03.018.

196. Henry LR, Sigurdson E, Ross EA, Lee JS, Watson JC, Cheng JD, et al. Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. *Annals of Surgical Oncology*. 2007;14(3):1081-91. doi: 10.1245/s10434-006-9266-7.

197. Bosman SJ, Vermeer TA, Dudink RL, de Hingh IH, Nieuwenhuijzen GA, Rutten HJ. Abdominosacral resection: long-term outcome in 86 patients with locally advanced or locally recurrent rectal cancer. *European Journal of Surgical Oncology*. 2014;40(6):699-705. doi: 10.1016/j.ejso.2014.02.233.

198. Ferenschild FT, Vermaas M, Verhoef C, Dwarkasing RS, Eggermont AM, de Wilt JH.

- Abdominosacral resection for locally advanced and recurrent rectal cancer. *The British Journal of Surgery*. 2009;96(11):1341-7. doi: 10.1002/bjs.6695.
199. Bhanu A, Brown G, Akmal M, Tekkis P. Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer. *The British Journal of Surgery*. 2012;99(10):1453-61. doi: 10.1002/bjs.8881.
200. Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? *Diseases of the Colon and Rectum*. 2013;56(1):14-9. doi: 10.1097/DCR.0b013e3182741929.
201. Alberda WJ, Verhoef C, Nuyttens JJ, Rothbarth J, van Meerten E, de Wilt JH, et al. Outcome in patients with resectable locally recurrent rectal cancer after total mesorectal excision with and without previous neoadjuvant radiotherapy for the primary rectal tumor. *Annals of Surgical Oncology*. 2014;21(2):520-6. doi: 10.1245/s10434-013-3306-x.
202. Bouchard P, Efron J. Management of recurrent rectal cancer. *Annals of Surgical Oncology*. 2010;17(5):1343-56. doi: 10.1245/s10434-009-0861-2.
203. Moore HG, Shoup M, Riedel E, Minsky BD, Alektiar KM, Ercolani M, et al. Colorectal cancer pelvic recurrences: determinants of resectability. *Diseases of the Colon and Rectum*. 2004;47(10):1599-606.
204. Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. *Cancer*. 2002;95(5):1144-50. doi: 10.1002/cncr.10799.
205. Koom WS, Choi Y, Shim SJ, Cha J, Seong J, Kim NK, et al. Reirradiation to the pelvis for recurrent rectal cancer. *Journal of Surgical Oncology*. 2012;105(7):637-42. doi: 10.1002/jso.23023.
206. Vermaas M, Nuyttens JJ, Ferenschild FT, Verhoef C, Eggermont AM, de Wilt JH. Reirradiation, surgery and IORT for recurrent rectal cancer in previously irradiated patients. *Radiotherapy and Oncology*. 2008;87(3):357-60. doi: 10.1016/j.radonc.2008.02.021.
207. Haddock MG, Miller RC, Nelson H, Pemberton JH, Dozois EJ, Alberts SR, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2011;79(1):143-50. doi: 10.1016/j.ijrobp.2009.10.046.
208. Roeder F, Goetz JM, Habl G, Bischof M, Krempien R, Buechler MW, et al. Intraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer. *BMC Cancer*. 2012;12:592. PMID: 3557137. doi: 10.1186/1471-2407-12-592.
209. Guo S, Reddy CA, Kolar M, Woody N, Mahadevan A, Deibel FC, et al. Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience. *Radiation Oncology*. 2012;7:110. PMID: 3430560. doi: 10.1186/1748-717X-7-110.
210. Lindel K, Willett CG, Shellito PC, Ott MJ, Clark J, Grossbard M, et al. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2001;58(1):83-7.
211. Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM, et al. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2000;48(1):219-26.